Evidence map›Paper›PMID 28211093›Full record

ArticleGenetic epidemiology2017

gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels.

Nicholas B Larson, Shannon McDonnell, Lisa Cannon Albright, Craig Teerlink, Janet Stanford, Elaine A Ostrander, William B Isaacs, Jianfeng Xu, Kathleen A Cooney, Ethan Lange and 22 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Genetic epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 8 countries.

Nicholas B LarsonDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Shannon McDonnellDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Lisa Cannon AlbrightDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Craig TeerlinkDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Janet StanfordFred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Elaine A OstranderNational Human Genome Research Institute, Bethesda, Maryland, United States of America.
William B IsaacsBrady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Jianfeng XuNorthShore University HealthSystem Research Institute, Chicago, Illinois, United States of America.
Kathleen A CooneyDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Ethan LangeDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Johanna SchleutkerDepartment of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, Turku, Finland.
John D CarptenDepartment of Translational Genomics, University of Southern California, Los Angeles, California, United States of America.
Isaac PowellDepartment of Urology, Wayne State University, Detroit, Michigan, United States of America.
Joan E Bailey-WilsonStatistical Genetics Section, National Human Genome Research Institute, Bethesda, Maryland, United States of America.
Olivier CussenotCeRePP, Hopital Tenon, Paris, France.
Geraldine Cancel-TassinCeRePP, Hopital Tenon, Paris, France.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
Robert J MacInnisCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
Christiane MaierDepartment of Urology, University of Ulm, Ulm, Germany.
Alice S WhittemoreDepartment of Health Research and Policy, Stanford University, Stanford, California, United States of America.
Chih-Lin HsiehDepartment of Urology, University of Southern California, Los Angeles, California, United States of America.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
William J CatalonaDepartment of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
William FoulkesDepartment of Oncology, Montreal General Hospital, Montreal, Quebec, Canada.
Diptasri MandalDepartment of Genetics, LSU Health Sciences Center, New Orleans, Louisiana, United States of America.
Rosalind EelesThe Institute of Cancer Research, London, UK.
Zsofia Kote-JaraiThe Institute of Cancer Research, London, UK.
Michael J AckermanDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Timothy M OlsonDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Christopher J KleinDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America.
Stephen N ThibodeauDepartment of Laboratory Medicine/Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.
Daniel J SchaidDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Mayo Clinic · USMayo Clinic in Florida · USInstitute of Cancer Research · GBNational Human Genome Research Institute · USSorbonne Université · FRUniversity of Southern California · USUniversity of Utah · USCancer Council Victoria · AUFred Hutch Cancer Center · USJohns Hopkins University · USKarolinska Institutet · SELouisiana State University Health Sciences Center New Orleans · USMichigan United · USMontreal General Hospital · CANorthShore University HealthSystem · USNorthwestern University · USStanford Health Care · USUniversität Ulm · DEUniversity of Melbourne · AUUniversity of Michigan–Ann Arbor · US

Funding

Prostate Cancer Susceptibility: The ICPCG StudyU01CA089600 · NCI · MAYO CLINIC ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 2002 to 2016
$27.3M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
Finding Genes for Human Prostate CancerZIAHG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2009 to 2021
$17.7M
Quantitative Methods for Genetic EpidemiologyR01GM065450 · NIGMS · MAYO CLINIC ROCHESTER · PI SCHAID, DANIEL J. · 2002 to 2020
$5.6M
Development of statistical genetics methodologyZIAHG000153 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BAILEY-WILSON, JOAN ELLEN · 2009 to 2022
$5.0M
NCI NIH HHS P50 CA180995NCI NIH HHS U01 CA089600NIGMS NIH HHS R01 GM065450
6 · The paper itself

Abstract

Next-generation sequencing technologies have afforded unprecedented characterization of low-frequency and rare genetic variation. Due to low power for single-variant testing, aggregative methods are commonly used to combine observed rare variation within a single gene. Causal variation may also aggregate across multiple genes within relevant biomolecular pathways. Kernel-machine regression and adaptive testing methods for aggregative rare-variant association testing have been demonstrated to be powerful approaches for pathway-level analysis, although these methods tend to be computationally intensive at high-variant dimensionality and require access to complete data. An additional analytical issue in scans of large pathway definition sets is multiple testing correction. Gene set definitions may exhibit substantial genic overlap, and the impact of the resultant correlation in test statistics on Type I error rate control for large agnostic gene set scans has not been fully explored. Herein, we first outline a statistical strategy for aggregative rare-variant analysis using component gene-level linear kernel score test summary statistics as well as derive simple estimators of the effective number of tests for family-wise error rate control. We then conduct extensive simulation studies to characterize the behavior of our approach relative to direct application of kernel and adaptive methods under a variety of conditions. We also apply our method to two case-control studies, respectively, evaluating rare variation in hereditary prostate cancer and schizophrenia. Finally, we provide open-source R code for public use to facilitate easy application of our methods to existing rare-variant analysis results.

Indexed as

AlgorithmsGenetic VariationComputer SimulationGenetic Association StudiesHumansModels, GeneticSample SizeStatistics, Nonparametricgene setnext-generation sequencingpathwayrare variation

Identifiers

PMID28211093
PMCPMC5397327
OpenAlexW2588066861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.